MK-2214 / Merck (MSD), Teijin - LARVOL DELTA

Drug Development. (PubMed, Alzheimers Dement) - "The preclinical profile presented here supports the clinical development of MK-2214 as an optimal tau antibody to slow the progression of AD."

Journal • Alzheimer's Disease • CNS Disorders

Phase 1 studies of MK-2214, a novel antibody targeting pS413 tau, for the treatment of Alzheimer's disease (CTAD 2025) - No abstract available

P1 data • Alzheimer's Disease • CNS Disorders

…the company announced that MK-2214, a novel candidate targeting the abnormal accumulation and aggregation of tau in the brain, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease. (Merck (MSD) Press Release)

Fast track • Alzheimer's Disease

Merck Showcases Data for Alzheimer’s Disease Candidates MK-2214 and MK-1167 at CTAD 2025 (Merck (MSD) Press Release) - "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer’s Disease (CTAD) 2025 in San Diego, California from Dec. 1-4."

P1 data • P2 data • Alzheimer's Disease

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) (clinicaltrials.gov) - P2 | N=340 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2029 ➔ Apr 2029 | Trial primary completion date: Sep 2029 ➔ Apr 2029

Enrollment open • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) (clinicaltrials.gov) - P1 | N=34 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) (clinicaltrials.gov) - P2 | N=340 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P2 trial • Alzheimer's Disease • CNS Disorders

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF P-tau

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Nov 2024 ➔ May 2025 | Trial primary completion date: Nov 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF P-tau

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF P-tau

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF P-tau